Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III

Overview of attention for article published in Orphanet Journal of Rare Diseases, June 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 1 news outlet
twitter: 8 X users

facebook: 2 Facebook pages

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 69 Mendeley

Summary News X Facebook Dimensions citations

So far, Altmetric has seen 1 news story.

Abeona Therapeutics: The Approval Pathway

Seeking Alpha, 02 Aug 2018

The market's expectations of the neurocognitive outcomes from the ongoing ABO-102 is unrealistic.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.